“Data is pretty much everything,” said Alminana, who is co-founder & COO of Elysium Health. “If you’re going to invest in something that you don’t feel immediately, you have to have a huge amount of trust that what you’re getting is what the company says they’re selling you.”
He added that being able to pair clinical data with tools that allow consumers to track how they are aging, is where the industry should be going—and definitely where Elysium is heading.
While wearables like Oura rings track everything, Alminana said consumers are drowning in data without clear direction. He believes artificial intelligence will solve this by weaving together wearable metrics, supplement habits and sleep patterns into personalized recommendations people can actually use.
The strategy behind Elysium’s success lies in prioritizing scientific credibility over flashy marketing, even when it costs short-term sales. The company has built its brand around rigorous human trials published in peer-reviewed journals and assembled world-renowned aging researchers on its advisory board. According to Alminana, this approach has paid off remarkably, with about 20% of its customers from 2015 remaining active a decade later.
Reflecting on the longevity market over the past decade, Alminana said consumers are much more educated on the topic, hungry for data and more willing to try these types of products now than they were 10 years ago.
“A few years ago, there were zero searches for NAD supplements on Amazon…like, zero,” he said. “Now, it’s about two to three million a month, so in a three or four year timeframe, it went from zero to millions.
“I think now people are starting to understand these topics, so then it’s just going to be about which product they feel like buying and again, this goes back to data. If one product has a clinical trial showing that it does what it says it does and the other one doesn’t, it’s a pretty easy choice.”
